Acellular Pertussis Completed Phase 3 Trials for Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (DB10788)

IndicationStatusPhase
DBCOND0031302 (Acellular Pertussis)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00489970Persistence Study of GSK Biologicals' Tdap Vaccine 1, 3, 5 and 9 Years Following Administration as an Initial Single Dose in Healthy Young Adults and to Evaluate the Immunogenicity and Safety of Boostrix as a Second Dose of Tdap, When Administered at Year 9Prevention
NCT00148941Immune Response and Safety Comparison of 3 Lots of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP + IPV VaccinesPrevention
NCT01577732Safety of GSK Biologicals' Infanrix-IPV+HibTM Vaccine in Healthy Vietnamese ToddlersPrevention
NCT00463437Pneumococcal Vaccine Booster Study in Healthy Children 11-18 Months Old Previously Primed With the Same VaccinesPrevention
NCT00835237Evaluation of GlaxoSmithKline Biologicals' Boostrix® Vaccine in Comparison With Decavac™ Vaccine.Prevention
NCT01353703Immunogenicity and Safety Study in Infants of GlaxoSmithKline Biologicals' Infanrix Hexa™ (DTPa-HBV-IPV/Hib) VaccinePrevention
NCT01309646Immunogenicity and Safety of GlaxoSmithKline Biologicals' Infanrix™-IPV+Hib VaccinePrevention
NCT02096263Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy InfantsPrevention
NCT00385255Immunogenicity, Safety of GSKs Tdap Vaccine Boostrix When Coadministered With GSKs Influenza Vaccine Fluarix in AdultsPrevention
NCT00290342Evaluation of the Immunogenicity, Safety and Reactogenicity of the Combined DTPa-IPV Vaccine in Healthy InfantsPrevention
NCT00346073Safety and Immunogenicity of GSK's Tdap Vaccine (Boostrix) in Adults Aged 19 to 64 YearsPrevention
NCT00871117Immunogenicity and Safety of Kinrix + (Measles Mumps Rubella) MMR Vaccine With and Without Varicella Vaccine in Healthy Children 4-6 YearsPrevention
NCT01245049Immunogenicity and Safety of GSK Biologicals' Boostrix Polio Vaccine in 3 and 4-year-old ChildrenPrevention
NCT01988857Safety of a Booster Dose of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Healthy Vietnamese ChildrenPrevention
NCT00325143Safety of DTPa-IPV/Hib & DTPa-HBV-IPV/Hib, Followed by DTPa-IPV/Hib Vaccine in Infants Who Received Hepatitis B VaccinePrevention
NCT00412854Study to Assess Safety & Immunogenicity of GSK Biologicals' DTPa/Hib Vaccine vs Separate Administration of DTPa and Hib.Prevention
NCT00696423Immunogenicity and Safety of GSK Biologicals' Infanrix/Hib in ChildrenPrevention
NCT00964028Safety Study of GSK Biologicals' DTPa-IPV/Hib (Infanrix™-IPV/Hib)Prevention
NCT00871000Immunogenicity and Safety of Boostrix Polio Vaccine as a Booster Dose in 5 to 6-year-old Children.Prevention
NCT01086423Immunogenicity and Safety Study of GSK Biologicals' Infanrix-IPV+Hib™ VaccinePrevention
NCT01449812Immunogenicity and Safety Study of Booster Dose of GSK Biologicals' IPV (Poliorix™) and DTPa/Hib (Infanrix+Hib™) VaccinePrevention
NCT01738477Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Previously Boosted Young AdultsPrevention
NCT01457560Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib Vaccine Followed by the Same Vaccine and Oral Polio VaccinePrevention
NCT01277705Comparison of GSK Biologicals' Reduced Antigen Diphtheria and Tetanus Toxoids and Acellular Pertussis- Inactivated Poliovirus Vaccine, to BoostrixTM and Inactivated Poliovirus Vaccine Administered Separately and With Revaxis®Prevention
NCT00879827Immunogenicity and Reactogenicity of GSK Bio DTPa-HBV-IPV and Hib Vaccines When Coadministered to Healthy InfantsPrevention
NCT00452686Study to Assess Safety & Immunogenicity of GSK Biologicals' Boostrix (dTpa) Vaccine vs. Chinese DT VaccinePrevention
NCT00406562Study to Assess the Safety & Reactogenicity of GSK Biologicals' dTpa Vaccine (Boostrix) When Given at 6-8 Years of Age.Prevention